Abstract:43 Background: Prostate cancer (PC) is a leading cause of cancer death in men worldwide. Imaging plays a key role in disease detection and initial staging. Emerging data has shown the superiority of 68 Gallium and 18 Fluorine labeled-PSMA imaging with PET/CT over conventional imaging for primary diagnosis. Despite the success, there are challenges in meeting the high demand and expensive costs especially in low-income countries. These challenges stimulated interest in 99m Technetium-labeled-PSMA agents. Single photon emission computer tomography (SPECT/CT) is more worldwide available, and the imaging agent is low cost, which is more promising. The aim of this study is to compare the diagnostic accuracy of 99m Tc‐PSMA-SPECT/CT to 18 F-PSMA-PET/CT in the primary diagnosis of PC and impact on clinical staging. Methods: Prospective controlled study, total of 16 patients with histologically confirmed PC (intermediate unfavorable and high risk) were recruited to undergo 18 F-PSMA-PET/CT and 99m Tc-HYNIC-PSMA-SPECT/CT. Mean age of patients was 71 (54-75) years and the median PSA level was 31.5 (4.3-920) ng/ml. Lesions were divided into prostate, seminal vesicles, lymph nodes (LN) (locoregional [LR] and non-locoregional [NLR]), bone, and visceral metastases. The size of LN with PSMA avidity on 99m Tc‐PSMA-SPECT/CT were determined. Lesions detected were read independently of PET/CT findings with two experienced nuclear medicine physicians. Volumetric analysis was also performed between the two imaging modalities (Tumoral Total Volume [TTV]) and correlated with PSA levels. Results: A total of 233 lesions were detected on 18 F-PSMA-PET/CT; prostate (n=16), seminal vesicles (n=11), LN LR (n=54), NLR (n=66), bone (n=82) and visceral (n=4); of these 99m Tc‐PSMA-SPECT/CT both reviewers detected 100% of the lesions in prostate (16/16), seminal vesicles (11/11) and visceral (4/4); LN LR (51/54; 94%), NLR (51/66; 77%) and bone (70/82; 85%). Between reviewers there was discordance in just 3 LN (<4 mm) and 1 bone metastases. The lowest diameter of positive LN detected by SPECT/CT was 4 mm (range 4-18). Pearson-correlation coefficient between PSA and TTV SPECT was r=0.68 (p=0.003) and for TTV PET r=0.71 (p=0.002). There were not statistically significant differences between TTV SPECT and TTV PET (T-student p=0.48). Five cases with high volume disease were detected by both methods. All patients were classified according to miTNM showing no difference. Conclusions: 99m Tc‐PSMA-SPECT/CT may be a useful in primary diagnosis of PC. Despite it showed a slightly lower lesion detection rate compared to 18 F-PSMA-PET/CT, it exhibited no impact on clinical staging and consequently the initial treatment intension. Our results show that 99m Tc‐PSMA-SPECT/CT could be used as a cost-efficient alternative with wider availability and no significant difference.

Preliminary Clinical Study of (99M)tc-Labelled Small Molecules Against PSMA for Prostate Cancer Imaging

Clinical value of 99mTc-PSMA SPECT/CT in detection of prostate cancer

Evaluation of Radiation dosimetry of 99mTc-HYNIC-PSMA and imaging in prostate cancer

Dosimetry estimation and preliminary clinical application of [99mTc]Tc-HYNIC-PSMA-XL-2 in prostate cancer

The imaging study of a small-molecular inhibitor targeting prostate speciifc membrane antigen

Prostate-specific membrane antigen SPECT-CT in patients with intermediate and high-risk prostate cancer in primary diagnosis: A comparative analysis with 18 F-PSMA PET/CT.

Preparation, Biological Evaluation, and First-in-Human Single-Photon Emission Computed Tomography (SPECT) Study of 99Mtc-Labeled Prostate-Specific Membrane Antigen (Psma)-Targeted Radiotracers Containing Triazole with Reduced Kidneys Accumulation

Evaluation of 99mTc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse.

Preparation And Biological Evaluation Of [Tc-99m]Tc-Cngu As A Psma-Targeted Radiotracer For The Imaging Of Prostate Cancer

Intra-Individual Comparison Of 18f-Psma-1007 And 18f-Fdg Pet/Ct In The Evaluation Of Patients With Prostate Cancer

[99cmTc]Tc-PSMA-I&S-SPECT/CT: experience in prostate cancer imaging in an outpatient center

Preparation and Biological Evaluation of [99mTc]Tc-CNGU as a PSMA-Targeted Radiotracer for the Imaging of Prostate Cancer

A Preclinical Study of an 125I-Labeled PSMA Ligand for Prostate-Cancer Puncture

Preparation and Biological Evaluation of [<sup>99m</sup>Tc]Tc-CNGU as a PSMA-Targeted Radiotracer for the Imaging of Prostate Cancer

A Preliminary Study of PSMA Fluorescent Probe for Targeted Fluorescence Imaging of Prostate Cancer

99Mtc-Labeling and Evaluation of a HYNIC Modified Small-Molecular Inhibitor of Prostate-Specific Membrane Antigen.

[99mTc]Tc-HYNIC-ALUG SPECT/CT in the initial staging of 227 consecutive patients with newly diagnosed prostate cancer: a 5-year monocentric retrospective study

(1) PSMA PET/CT and standard plus PET/CT-Ultrasound fusion targeted prostate biopsy can diagnose clinically significant prostate cancer in men with previous negative biopsies (2) PSMA PET/CT-Ultrasound prostate biopsy

Preparation of 68Ga-Psma-11 with a Synthesis Module for Micro PET-CT Imaging of PSMA Expression During Prostate Cancer Progression.

68Ga-Psma-11 PET/CT for Prostate Cancer Staging and Risk Stratification in Chinese Patients

Initial Experience of Clinical Use of [99mTc]Tc-PSMA-T4 in Patients with Prostate Cancer. A Pilot Study